CLLS - Cellectis S.A.
| Previous Close | 9.84 |
| Open | 9.71 |
| Bid | 9.73 x 800 |
| Ask | 16.86 x 800 |
| Day's Range | 9.61 - 10.03 |
| 52 Week Range | 9.50 - 28.24 |
| Volume | 42,759 |
| Avg. Volume | 114,656 |
| Market Cap | 421.195M |
| Beta (3Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.24 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.10 |
- GuruFocus.com
2 Falling Knives Expected to Rebound
These companies have a moderate to low financial burden Continue reading...
- Business Wire
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates
Cellectis (ALCLS.PA) (CLLS) (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), and Lonza (LONN.SW), announced today that the companies have entered into a manufacturing service agreement covering clinical manufacturing of Cellectis’ allogeneic UCART product candidates targeting hematological malignancies. Lonza is in charge of implementing Cellectis’ manufacturing processes as per current Good Manufacturing Practices (cGMP) in a way that meets the highest quality and safety standards outlined by the FDA.
- Business Wire
Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019
Regulatory News:
- Business Wire
Cellectis Reports Financial Results for First Quarter 2019
- Started construction of in-house manufacturing facilities IMPACT and SMART
- Business Wire
Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting
- Oral presentation to include preclinical UCARTCS1A data in Multiple Myeloma
- Benzinga
The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...
- Business Wire
FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients
Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for UCARTCS1, in patients with multiple myeloma (MM). The IND for UCARTCS1 was filed on December 28, 2018 and approved by the FDA within a month, on January 25, 2019. Cellectis is the sponsor of the UCARTCS1 clinical study (MUNDI-01) and successfully ensured the manufacturing and release of UCARTCS1 GMP batches, as well as an IRB approval.
- Business Wire
Cellectis Reports 4th Quarter and Full Year 2018 Financial Results
NEW YORK-- -- UCART123 in Phase 1 dose escalation clinical trial ongoing for AML; UCART22 received FDA and IRB approvals for Phase 1 dose escalation clinical trial in B-ALL patients; UCART19 ASH abstract by partners Servier and Allogene showed continued progress of first clinical allogeneic CAR T-cell program for ALL adult and pediatric patients; Cellectis, through its new subsidiary Cellectis Biologics, ...
- Business Wire
Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio
Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it has entered into a lease agreement to build an 82,000 square foot commercial-scale manufacturing facility named IMPACT (Innovative Manufacturing Plant for Allogeneic Cellular Therapies) in Raleigh, North Carolina, for clinical and commercial production of Cellectis’ leading allogeneic UCART products. In addition, Cellectis started building a 14,000 square foot manufacturing facility in Paris, France named SMART (Starting Material Realization for CAR-T products) to produce Cellectis’ critical starting material supply for UCART clinical studies and commercial products.
- Motley Fool
5 Top Gene-Editing Stocks for 2019
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
- Business Wire
Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry
Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-Cells prevents monocyte-dependent release of key cytokine release syndrome mediators
- GlobeNewswire
Consolidated Research: 2019 Summary Expectations for Oceaneering International, Southwest Gas, WellCare Health Plans, Barnes & Noble, Cellectis S.A, and Payment Data — Fundamental Analysis, Key Performance Indications
NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
